{"id":"dha-piperaquine-and-a-sld-pq","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL539666","moleculeType":"Small molecule","molecularWeight":"633.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dihydroartemisinin (DHA) is a fast-acting artemisinin derivative that rapidly reduces parasite biomass by generating reactive oxygen species and damaging parasite proteins and membranes. Piperaquine is a bisquinoline that accumulates in parasitized red blood cells and inhibits heme detoxification, leading to parasite death. The combination provides synergistic activity with rapid parasite clearance and extended post-treatment prophylaxis.","oneSentence":"DHA/piperaquine is a fixed-dose artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms, while SLD-PQ (second-line drug with piperaquine) provides additional antimalarial activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:38.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by other Plasmodium species (P. vivax, P. ovale, P. malariae, P. knowlesi)"}]},"trialDetails":[{"nctId":"NCT06068530","phase":"PHASE4","title":"Mass Vaccine and Drug Administration, Bangladesh","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-15","conditions":"Plasmodium Falciparum Malaria","enrollment":10000},{"nctId":"NCT04864444","phase":"NA","title":"Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-06-19","conditions":"Malaria,Falciparum, Malaria","enrollment":10715}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DHA/piperaquine and a SLD-PQ","genericName":"DHA/piperaquine and a SLD-PQ","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DHA/piperaquine is a fixed-dose artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms, while SLD-PQ (second-line drug with piperaquine) provides additional antimalarial activity. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by other Plasmodium species (P. vivax, P. ovale, P. malariae, P. knowlesi).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}